Helen Winsor | 03/02/2011
Janos Szebeni, Director of the Nanomedicine Research and Education Center, Bay Zoltan Foundation for Applied Research at Semmelweis University, Budapest, joins Helen Winsor Pharma IQ, to discuss developments in immunogenicity. In this exclusive interview, Szebeni talks about the aims of his current research and how this will affect our current understanding of immunogenicity. He outlines the main challenges faced and the best practice methods that have been put in place to overcome these...
To continue reading this story Click Here
RECOMMENDED
MSD announces Phase III data on investigational treatment to lower LDL Cholesterol (LDL-C)
2025-11-17
AI for Pharma & Healthcare 2025
2025-06-18
Upcoming Events
Pharma Contract Manufacturing
23 - 25 March 2026
Mercure Hotel MOA Berlin, Germany
Register Now |
View Agenda |
Learn More